Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Has Mindray Medical Become the Perfect Stock?

By Dan Caplinger - Nov 6, 2012 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Finding companies that have all the right stuff can produce winners.

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, and then decide if Mindray Medical ( MR ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that the company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Mindray Medical.

Factor

What We Want to See

Actual

Pass or Fail?

Growth

Five-year annual revenue growth > 15%

25.5%

Pass

 

One-Year revenue growth > 12%

21.8%

Pass

Margins

Gross margin > 35%

55.7%

Pass

 

Net margin > 15%

17%

Pass

Balance sheet

Debt to equity < 50%

11.2%

Pass

 

Current ratio > 1.3

3.44

Pass

Opportunities

Return on equity > 15%

14.6%

Fail

Valuation

Normalized P/E < 20

32

Fail

Dividends

Current yield > 2%

1.2%

Fail

 

Five-year dividend growth > 10%

21.7%

Pass

       
 

Total Score

 

7 out of 10

Source: S&P Capital IQ. Total score = number of passes.

Since we looked at Mindray Medical last year, the company has lost a point, with a drop in return on equity leading to the decline. But the stock has done reasonably well, gaining 20% over the past year.

Mindray is a Chinese manufacturer of basic medical equipment, including patient monitoring and diagnostic devices, as well as ultrasound and other imaging systems. Given the strength in the Chinese economy over the past decade, Mindray has had a healthy market to tap.

But Mindray isn't free of competition. U.S. medical-device makers General Electric ( GE -2.58% ), Abbott Labs ( ABT 1.47% ), and Johnson & Johnson ( JNJ 1.46% ) are just a few of the companies looking to Chinese operations for growth opportunities. If anything, competition will only get fiercer as more companies realize the potential of the Chinese market.

Mindray has had mixed results on the earnings front over the past year. In May, the company had strong revenue growth but missed on profit estimates. Then, in August, Mindray boosted its guidance, sending shares soaring. Yet just yesterday, Mindray fell short on both the top and bottom lines, leaving investors wondering what the next step may be.

For Mindray to improve, it needs to get its earnings power to catch up with its somewhat expensive stock price. Until that happens, it'll be hard for Mindray to make much more progress toward becoming a perfect stock.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfection than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate the best investments from the rest.

Click here to add Mindray Medical to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mindray Medical International Limited Stock Quote
Mindray Medical International Limited
MR
General Electric Company Stock Quote
General Electric Company
GE
$92.77 (-2.58%) $-2.46
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$159.38 (1.46%) $2.29
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$130.27 (1.47%) $1.89

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.